



US 20210260059A1

(19) **United States**(12) **Patent Application Publication**
CAPONIGRO et al.(10) **Pub. No.: US 2021/0260059 A1**(43) **Pub. Date: Aug. 26, 2021**(54) **MDM2 INHIBITORS AND COMBINATIONS
THEREOF**(71) Applicant: **NOVARTIS AG**, Basel (CH)(72) Inventors: **Giordano CAPONIGRO**, Foxborough,
MA (US); **Ensar HALILOVIC**,
Canton, MA (US); **Thomas**
HORN-SPIROHN, Cambridge, MA
(US); **Joseph LEHAR**, Lexington, MA
(US)(21) Appl. No.: **17/188,726**(22) Filed: **Mar. 1, 2021****Related U.S. Application Data**(63) Continuation of application No. 15/756,094, filed on
Feb. 28, 2018, now abandoned, filed as application
No. PCT/IB2016/055050 on Aug. 24, 2016.(60) Provisional application No. 62/250,574, filed on Nov.
4, 2015, provisional application No. 62/243,337, filed
on Oct. 19, 2015, provisional application No. 62/211,
080, filed on Aug. 28, 2015.**Publication Classification**(51) **Int. Cl.****A61K 31/506** (2006.01)**A61K 31/496** (2006.01)**A61K 31/519** (2006.01)**A61K 31/5375** (2006.01)**A61P 35/00** (2006.01)**A61K 31/337** (2006.01)**A61K 31/4184** (2006.01)**A61K 31/4412** (2006.01)**A61K 31/4439** (2006.01)**A61K 31/517** (2006.01)**A61K 31/5377** (2006.01)**A61K 31/635** (2006.01)(52) **U.S. Cl.**CPC **A61K 31/506** (2013.01); **A61K 31/496**
(2013.01); **A61K 31/519** (2013.01); **A61K**
31/5375 (2013.01); **A61P 35/00** (2018.01);
A61K 31/635 (2013.01); **A61K 31/4184**
(2013.01); **A61K 31/4412** (2013.01); **A61K**
31/4439 (2013.01); **A61K 31/517** (2013.01);
A61K 31/5377 (2013.01); **A61K 31/337**
(2013.01)

(57)

ABSTRACT

The present disclosure relates to a pharmaceutical combination comprising (a) an Mdm2 inhibitor and (b)(i) a MEK inhibitor and/or (b)(ii) Bcl2 inhibitor, particularly for use in the treatment of a cancer. This disclosure also relates to uses of such combination for preparation of a medicament for the treatment of a cancer; methods of treating a cancer in a subject in need thereof comprising administering to said subject a jointly therapeutically effective amount of said combination; pharmaceutical compositions comprising such combination and commercial packages thereto.

Treatments ♦ COMPOUND A ▲ trametinib ♦ COMPOUND A+trametinib